aristopharma.orgAristo Pharma

-- Home Contact Us -- Home | Contact Us -- [google-translator] -- Global Presence French -- Newsletter subscribe -- -- -- Home About Us Products R & D CSR Global Knowledge Desk Payments Contact Us Medical Conference Home Page   -- Updates ARISTO has registered highest growth rate (14.55%) among top 12 pharmaceutical companies in India (Source-IMS MAT April 2017) ARISTO is ranked No. 3 in its covered market (Source-IMS MAT April 2017) ARISTO continues to be among the top 10 companies of India as per SMSRC prescription audit ARISTO has introduced India’s 1st ready-to-use, multi-dose probiotic formulation ‘Darolac Syrup’ in association with Royal Holloway University of London ARISTO has launched ready-to-drink, WHO recommended ORS formula ‘Olyte ORS’. ARISTO has entered anticoagulant segment with the launch of ‘Fondum’ PFS -- left sidebar ARISTO at a Glance.... Revenues (US $ Million) : 383 -- Market Share in Indian Pharma Market : 2.70% Growth : 16.81% CAGR (4 years) : 11.70% Rank in Indian Pharma market : 11 -- Market Share in covered market : 5.67% Rank in covered market : 3 Front Line Sales Force : Market Performance Market Performance Close YEAR : SEPT'18 - AUG'19 VAL (US$ Million) MARKET SHARE % RANK THERAPY Anti-infectives 214.93 10.86 2 Gastro Intestinal 82.43 4.52 6 Cardiac 42.73 2.06 18 Pain / Analgesics 20.32 1.53 23 Respiratory 20.09 1.42 20 Anti Diabetic 17.85 1.05 23 Vitamins / Minerals / Nutrients 14.78 1.06 29 Gynaec. 12.87 1.58 17 Neuro / CNS 11.27 1.11 16 Derma 9.55 0.71 33 Urology 4.85 1.50 18 Anti malarials 2.58 4.43 5 Blood Related 2.17 1.54 17 Anti-Parasitic 1.27 2.49 8 Hormones 1.07 0.39 18 Ophthal / Otologicals 0.57 0.18 41 Antineoplast / Immunomodulator 0.21 0.13 46 Source: Stockist Secondary Audit IMS - AUG MAT-™19 Dataset ARISTO has been consistently growing faster than the Indian Pharma Market. This makes us the 3 rd largest company in the product segments where we have our presence (IMS-MAT August 2019, covered market data). Corporate Standing Corporate Standing Close CORPORATIONS YEAR : SEPT'18 - AUG'19 Val in US$ Million Market Share % Growth(%) IPM TOTAL 16998 100.00 10.69 SUN 1,293 7.60 7.63 ABBOTT 1,075 6.32 10.48 CIPLA 832 4.89 9.55 MANKIND 693 4.08 8.43 ALKEM 654 3.85 18.23 LUPIN LIMITED 619 3.64 11.56 TORRENT PHARMA 570 3.35 9.80 MACLEODS PHARMA 561 3.30 7.79 INTAS PHARMA 516 3.04 15.06 ZYDUS CADILA 514 3.02 7.21 GLAXOSMITHKLINE 479 2.82 8.54 ARISTO PHARMA 460 2.70 16.81 DR REDDYS LABS 379 2.23 12.01 GLENMARK PHARMA 370 2.18 12.13 U S V 345 2.03 9.91 EMCURE 339 1.99 9.79 PFIZER 319 1.88 6.95 SANOFI 305 1.79 8.21 ALEMBIC 283 1.66 11.66 MICRO LABS 272 1.60 12.84 IPCA LABS 268 1.58 10.29 WOCKHARDT LTD 194 1.14 -9.98 FDC 188 1.11 5.31 HIMALAYA DRUG 158 0.93 6.32 ERIS LIFESCIENCES 150 0.88 13.98 NOVARTIS INTL. 148 0.87 0.27 FRANCO INDIAN 146 0.86 14.07 CADILA PHARMA 134 0.79 3.05 INDOCO 132 0.78 11.98 MSD PHARMACEUTICA 124 0.73 1.41 Source: Stockist Secondary Audit IMS - AUG MAT-™19 Dataset Having grown consistently year over year, we have reached the league of top ten Indian owned pharma organisations by turnover (IMS-MAT August 2019). We have achieved this distinction despite operating with only 5 marketing divisions to promote our product portfolio. On the prescription front, we are ranked 9 th (SMSRC prescription audit MAT August 2019) which reflects the trust that the medical fraternity has in us. Brand Power Brand Power Close Ten brands in top 300 products of Indian Pharma Market BRANDS YEAR : SEPT'18 - AUG'19 MOLECULE RANK* VAL in US $ Million ARISTO TOTAL * 459.55 MONOCEF CEFTRIAXONE 10 48.78 MIKACIN AMIKACIN 32 29.49 PANTOP-D PANTOPR.+ DOMPERID. 53 24.72 PANTOP PANTOPRAZOLE 61 22.98 MONOCEF-O CEFPODOXIME 64 22.50 MONOCEF-SB CEFTRIAXONE+SULBACTAM 92 18.78 MONTAZ CEFTRIAXONE + TAZOBACTAM 104 17.74 MEGA-CV AMOXYCILLIN + CLAVULANIC 133 14.63 ARISTOZYME DIGESTIVE ENZYMES 144 14.03 MEGAPEN AMPICILLIN + CLOXACILLIN 173 12.90 *Rank in total Indian Pharma Market Source: Stockist Secondary Audit IMS - AUG MAT-™19 Dataset ARISTO believes in building and nurturing brands to a leadership position in respective segments. The efforts in this direction have made ten brands feature in the coveted top 300 brands of the Indian Pharma Market. Development & Innovation Development & Innovation Close PROTONE FIRST Protein liquid in India ARISTOGYL FIRST Metronidazole Oral Liquid in India ARISTOZYME FIRST Fungal Diastase Liquid in India MIKACIN FIRST Amikacin in India MONOCEF FIRST Ceftriaxone in India GLIMIPREX MF FIRST Bilayer Glimepiride/Metformin SR in India MELOSET FIRST Melatonin in India ALFA OSTEBON FIRST Alfacalcidol/Calcium combination in India BUTRUM FIRST Butorphanol in India PANTOP HP FIRST Anti-HP kit formulation in India GABANEURON FIRST Gabapentin/Methylcobalamine in India ATCHOL ASP FIRST Atorvastatin/ Aspirin in India MONTAZ FIRST Ceftriaxone/Tazobactum injection in India FOLINEXT D FIRST Folic Acid/DHA combination in India CLINGEN FIRST Clindamycin/Clotrimazole Vaginal Cap in India DAROLAC IBS FIRST Lp299v in India ZEROTUSS FIRST Levocloperastine in India VASONEXT FIRST Nattokinose/Tocotrienol/EPA/DHA/Mixed Tocopherols combination DAROLAC Syrup FIRST Ready-to-use, Multi-dose probiotic in India FOLINEXT FIRST Optimum dose folic acid/Methylcobalamin combination Right since its inception, ARISTO has believed in introducing well differentiated formulations backed by its innovative R&D team. As a result, till date, ARISTO has the distinction of introducing over 20 formulations for the first time in India. right sidebar [iwg_maps zoom_level="2" zoom_longitude= "70" zoom_latitude="5"] -- Disclaimers Employee Portal Field Staff Portal Manufacturing Sitemap   -- © ARISTO Pharmaceuticals Private Limited error: Content is protected !!...